English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Despite the existence of vaccinations, diagnostic tools and treatments, tuberculosis (TB) prevalence is increasing because of the increased circulation of people, the misuse of antibacterials giving rise to growing numbers of drug resistant strains of Mycobacterium tuberculosis, low compliance with the lengthy therapy four different drugs for six months, and deadly liaisons with other health concerns (AIDS, diabetes, cancer, etc.). There is therefore a pressing need to look for new strategies against TB, in the hope of finding new drugs with novel mechanisms of action or ways to potentiate the activity of existing drugs and to reduce treatment duration. Recently, among the class of lasso peptides, interesting stable cyclic peptides of bacterial origin were reported, including the anti-mycobacterial lariatins A and B, followed by the newly-discovered anti-TB pseudo-lasso peptide lassomycin [1-3]. Furthermore the identification in M. tuberculosis of an orthologue of an enzyme found in E. coli [4,5] involved in peptidoglycan recycling encouraged us to try to identify and evaluate its activity and find potential inhibitors.

Lasso Peptides and Murein Peptide Ligase Inhibitors as Novel Anti-Mycobacterial Agents